Glycosaminoglycans can be associated with oxidative damage in mucopolysaccharidosis II patients submitted to enzyme replacement therapy (original) (raw)

• Barschak AG, Sitta A, Deon M, et al. Evidence that oxidative stress is increased in plasma from patients with maple syrup urine disease. Metab Brain Dis. 2006;21(4):279–86.
  Article CAS PubMed Google Scholar
• Beckman KB, Ames BN. The free radical theory of aging matures. Physiol Rev. 1998;78(2):547–81.
  CAS PubMed Google Scholar
• Berry HK. Screening for mucopolysaccharide disorders with the Berry spot test. Clin Biochem. 1987;20:365–71.
  Article CAS PubMed Google Scholar
• Biancini GB, Vanzin CS, Rodrigues DB, et al. Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy. Biochim Biophys Acta. 2012;1822:226–32.
  Article CAS PubMed Google Scholar
• Blau N, Duran M, Blaskovics ME, et al. Approach to diagnosis. Simple tests in urine and blood. In: Blau N et al., editors. Physician’s guide to the laboratory diagnosis of metabolic diseases. New York: Chapman & Hall Medical; 1996. p. 3–12.
• Coelho JC, Wajner M, Burin MG, et al. Selective screening of 10000 high-risk Brazilian patients for the detection of inborn errors of metabolism. Eur J Pediatr. 1997;156:650–4.
  Article CAS PubMed Google Scholar
• Deganuto M, Pittis MG, Pines A, et al. Altered intracellular redox status in Gaucher disease fibroblasts and impairment of adaptive response against oxidative stress. J Cell Physiol. 2007;212(1):223–35.
  Article CAS PubMed Google Scholar
• Di Domenico C, Villani GR, Di Napoli D, et al. Intracranial gene delivery of LV-NAGLU vector corrects neuropathology in murine MPS IIIB. Am J Med Genet A. 2009;149A(6):1209–18.
  Article PubMed Google Scholar
• Esterbauer, Cheeseman KH. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymol. 1990;186:407–21.
  Article CAS PubMed Google Scholar
• Germain DP. Enzyme replacement therapies for lysosomal storage disorders. Med Sci. 2005;21(11):77–83.
  Google Scholar
• Giugliani R, Rojas VM, Martins AM, et al. A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I. Mol Genet Metab. 2009;96(1):13–9.
  Article CAS PubMed Google Scholar
• Halliwell B, Gutteridge JMC, editors. Free radicals in biology and medicine. Oxford: Oxford University Press; 2007.
  Google Scholar
• Harmatz P, Giugliani R, Schwartz IV, et al. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab. 2008;94(4):469–75.
  Article CAS PubMed Google Scholar
• Jong JG, Wevers RA, Liebrand-van Sambeek R. Measuring urinary glycosaminoglycans in the presence of protein: an improved screening procedure for mucopolysaccharidoses based on dimethylmethylene blue. Clin Chem. 1992;38(6):803–7.
  PubMed Google Scholar
• Kakkis ED, Muenzer J, Tiller GE, et al. Enzyme replacement therapy in mucopolysaccharidosis I. N Eng J Med. 2001;344:182–8.
  Article CAS Google Scholar
• Mabe P, Valiente A, Soto V, et al. Evaluation of reliability for urine mucopolysaccharidosis screening by dimethylmethylene blue and Berry spot tests. Clin Chim Acta. 2004;345:135–40.
  Article CAS PubMed Google Scholar
• Muenzer J, Gucsavas-Calikoglu M, McCandless SE, et al. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metab. 2007;90(3):329–37.
  Article CAS PubMed Google Scholar
• Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic basis of inherited disease. New York: McGraw Hill; 2001.
  Google Scholar
• Pereira VG, Martins AM, Micheletti C, D’Almeida V. Mutational and oxidative stress analysis in patients with mucopolysaccharidosis type I undergoing enzyme replacement therapy. Clin Chim Acta. 2008;387(1–2):75–9.
  Article CAS PubMed Google Scholar
• Ribas GS, Pires R, Coelho JC, et al. Oxidative stress in Niemann-Pick type C patients: a protective role of N-butyl-deoxynojirimycin therapy. Int J Dev Neurosci. 2012;30(6):439–44.
  Article CAS PubMed Google Scholar
• Roversi FM, Galdieri LC, Grego BHC, Souza FG, Micheletti C, Martins AM, et al. Blood oxidative stress markers in Gaucher disease patients. Clin Chim Acta. 2006;364(1–2):316–20.
  Article CAS PubMed Google Scholar
• Shen JS, Meng XL, Moore DF, et al. Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol Genet Metab. 2008;95(3):163–8.
  Article CAS PubMed Central PubMed Google Scholar
• Singh N, McCoy M, Tice R, Schneider E. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res. 1988;175(1):184–91.
  Article CAS PubMed Google Scholar
• Sitta A, Barschak AG, Deon M, et al. Investigation of oxidative stress parameters in treated phenylketonuric patients. Metab Brain Dis. 2006;21(4):287–96.
  Article CAS PubMed Google Scholar
• Vargas CR, Wajner M, Sirtori LR, et al. Evidence that oxidative stress is increased in patients with X-linked adrenoleukodistrophy. Biochim Biophys Acta. 2004;1688(1):26–32.
  Article CAS PubMed Google Scholar
• Voznyi YV, Keulemans JL, van Diggelen OP. A fluorimetric enzyme assay for the diagnosis of MPS II (Hunter disease). J Inherit Metab Dis. 2001;24(6):675–80.
  Article CAS PubMed Google Scholar